| Valid Data Submission Method(s) | Measure Type | High Priority Measure? | NQS Domain | Specialty Measure Sets |
|---|---|---|---|---|
| Claims, Registry | Structure | No | Effective Clinical Care | Pathology |
Measure Description
This is a measure based on whether quantitative evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) by immunohistochemistry (IHC) uses the system recommended in the current ASCO/CAP Guidelines for Human Epidermal Growth Factor Receptor 2 Testing in breast cancer
Instruction
This measure should be reported each time a quantitative HER2 IHC pathology examination is performed during the performance period for patients with breast cancer; however, only one quality-data code (QDC) per date of service for a patient is required. This measure may be reported by eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding.
Denominator
All breast cancer patients with quantitative breast tumor evaluation by HER2 IHC
Denominator Criteria (Eligible Cases):
Diagnosis for breast cancer (ICD-10-CM): C50.011, C50.012, C50.019, C50.021, C50.022, C50.029, C50.111, C50.112, C50.119, C50.121, C50.122, C50.129, C50.211, C50.212, C50.219, C50.221, C50.222, C50.229, C50.311, C50.312, C50.319, C50.321, C50.322, C50.329, C50.411, C50.412, C50.419, C50.421, C50.422, C50.429, C50.511, C50.512, C50.519, C50.521, C50.522, C50.529, C50.611, C50.612, C50.619, C50.621, C50.622, C50.629, C50.811, C50.812, C50.819, C50.821, C50.822, C50.829, C50.911, C50.912, C50.919, C50.921, C50.922, C50.929
AND
Patient procedure during the performance period (CPT): 88360, 88361
AND NOT
DENOMINATOR EXCLUSION:
Quantitative non-HER2 IHC evaluation (eg, testing for estrogen or progesterone receptors, [ER/PR]) performed: 3395F
Numerator
Breast cancer patients receiving quantitative breast tumor HER2 IHC evaluation using the ASCO/CAP recommended manual system or a computer-assisted system consistent with the optimal algorithm for HER2 testing as described in the current ASCO/CAP guideline
Numerator Options:
Performance Met: Quantitative HER2 by IHC evaluation consistent with
scoring system defined in the ASCO/CAP guidelines
(3394F)
OR
Performance Not Met: Quantitative evaluation of HER2 did not use the system
recommended in the ASCO/CAP Guidelines for Human
Epidermal Growth Factor Receptor 2 Testing in breast
cancer, reason not otherwise specified (3394F with 8P)